New Research Report - Multiple Myeloma Therapeutics in Major Developed Markets to 2021 - Growth Driven by Rising Prevalence

ResearchMoz added Latest Research Report titled " Multiple Myeloma Therapeutics in Major Developed Markets to 2021 - Growth Driven by Rising Prevalence, Continued Success of Revlimid and Emerging Supplementary Treatments " to it's Large Report database.

Multiple Myeloma (MM) is a hematological malignancy characterized by the proliferation of plasma cells in the bone marrow. It is the second-most frequently diagnosed hematological malignancy, with an annual prevalence in the US of about 45,000. The disease is considered incurable, although the past decade has seen significant improvements in therapy, driven by a greater understanding of pathophysiology. Many of the leading drugs in the market were approved over the past 10–15 years, and have improved median survival rates by about 50%.

The MM pipeline contains 267 products in active development, encompassing a range of molecule types and therapeutic targets. The innovation that has characterized the market over recent years is also clearly present in the current pipeline, with a strong presence of novel, targeted products.

Download free Sample PDF report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=316442

Scope
  • The MM market landscape has undergone significant change over the past two decades.
  • Which classes of drug have emerged to dominate the market?
  • What survival benefits have these drugs produced?
  • How do the leading marketed therapies compare clinically?
  • The pipeline contains a range of molecule types and molecular targets not present in the current market, including a strong focus on therapies targeting common oncogenic pathways, such as the Phosphoinositide 3-Kinase/Protein Kinase B (PI3K/Akt) pathway.
  • Which molecular targets appear most frequently in the pipeline?
  • How will the new therapies be positioned in the treatment of MM?
  • How have selected late-stage pipeline therapies performed in clinical trials?
  • MM clinical trials have an overall attrition rate of 78%.
  • What are the failure rates for individual Phases of clinical development?
  • How do MM clinical trial characteristics, including failure rate, duration, and size compare against oncology and industry averages?
Read All Pharmaceutical Market Research Reports @ http://www.researchmoz.us/pharmaceutical-market-reports-38.html

Table of Contents

1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 7

2 Introduction 9
2.1 Disease Introduction 9
2.2 Etiology 9
2.3 Pathophysiology 9
2.4 Symptoms 11
2.5 Diagnosis and Classification 11
2.6 Epidemiology 14
2.7 Prognosis and Disease Staging 15
2.8 Treatment Options 17
2.8.1 Treatment Algorithm 19
2.8.2 Initial Therapy for Newly Diagnosed Symptomatic Disease 19
2.8.3 Maintenance Therapy 22
2.8.4 Therapy for Relapsed or Refractory Myeloma 24

3 Marketed Products 29
3.1 Overview 29
3.2 Immunomodulatory Agents 29
3.2.1 Thalomid (thalidomide) – Celgene 29
3.2.2 Revlimid (lenalidomide) – Celgene 30
3.2.3 Pomalyst (pomalidomide) – Celgene 30
3.3 Proteasome Inhibitors 31
3.3.1 Velcade (bortezomib) – Millennium Pharmaceuticals/Takeda 31
3.3.2 Kyprolis (carfilzomib) – Onyx 31

About ResearchMoz

ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket
Albany NY - 12207
United States
Tel: +1-518-621-2074
Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
New Research Report - Multiple Myeloma Therapeutics in Major Developed Markets to 2021 - Growth Driven by Rising Prevalence New Research Report - Multiple Myeloma Therapeutics in Major Developed Markets to 2021 - Growth Driven by Rising Prevalence Reviewed by Sagar Jagtap on 02:55 Rating: 5

No comments:

Powered by Blogger.